source
- Vedanta Biosciences secures $60 million to complete Phase 3 trial of C. difficile microbiome therapyVedanta Biosciences, a Cambridge, MA biotech focused on microbiome therapeutics, announced it has raised $60 million in new financing. The capital will be used to advance its lead candidate target…
- Moderna delays norovirus vaccine readout, cites insufficient infectionsModerna announced that its norovirus vaccine trial will not yield efficacy data this season because infection rates were lower than expected. The company said it will open an additional trial coho…